Arena Capital Advisors’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Arena Capital Advisors’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-100,000	Closed	-$6.39K	–	157
2022 Q4	$6.39K	Hold	100,000	–	–	﹤0.01%	105
2022 Q3	$6K	Hold	100,000	–	–	﹤0.01%	178
2022 Q2	$9K	Hold	100,000	–	–	﹤0.01%	224
2022 Q1	$24K	Hold	100,000	–	–	﹤0.01%	245
2021 Q4	$66K	Hold	100,000	–	–	0.01%	293
2021 Q3	$66K	Buy	+100,000	New	+$74.4K	0.01%	319

Arena Capital Advisors's BIOTW Position: Q1 2023 in Review

Arena Capital Advisors sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 100,000 shares — an estimated $6.39K sold.

Arena Capital Advisors first reported a position in BIOTW in Q3 2021 and held it in 6 quarters. The position peaked at $66K in Q4 2021. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Arena Capital Advisors reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Arena Capital Advisors sold 100,000 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $6.39K.
Arena Capital Advisors first reported a position in Biotech Acquisition Company Warrant in Q3 2021 and held it in 6 quarters.
Arena Capital Advisors's Biotech Acquisition Company Warrant position peaked at $66K in Q4 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Arena Capital Advisors's 13F filing for Q1 2023, filed 12 May 2023.